FDA Drug Recalls

Recalls / Class II

Class IID-1280-2014

Product

Fluoxetine Capsules USP, 20 mg, packaged in a) 100-count bottles (NDC 50111-648-01), b) 500-count bottles (NDC 50111-648-02), c) 1000-count bottles (NDC 50111-648-03), and d) 2000-count bottles (NDC 50111-648-44), Rx only, Manufactured in Poland By: Pliva Krakow Pharmaceutical Company S.A., Krakow, Poland; Manufactured For: Teva Pharmaceuticals USA, Sellersville, PA 18960.

Brand name
Fluoxetine
Generic name
Fluoxetine
Active ingredient
Fluoxetine Hydrochloride
Route
Oral
NDCs
50111-647, 50111-648
FDA application
ANDA076001
Affected lot / code info
Lot #: a) 6A211150, 6A211151, 6A211152, 6A211153, 6A211154, Exp 11/15; 6A212083, 6A212084, 6A212085, 6A212086, Exp 12/15; b) 6A211143, 6A211145, 6A211146, 6A211147, Exp 11/15; c) 6A209116, 6A209117, 6A209118, 6A209119, 6A209120, Exp 09/15; 6A211139, 6A211140, 6A211141, Exp 11/15; 6A212087, Exp 12/15; d) 6A209124, Exp 09/15; 6A211144, 6A211148, 6A211149, Exp 11/15

Why it was recalled

Chemical Contamination: Recall due to a customer complaint trend regarding capsule odor.

Recalling firm

Firm
Teva Pharmaceuticals USA
Manufacturer
Teva Pharmaceuticals USA, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
425 Privet Rd, Horsham, Pennsylvania 19044-1220

Distribution

Quantity
257904 bottles
Distribution pattern
Nationwide and Puerto Rico

Timeline

Recall initiated
2014-02-12
FDA classified
2014-04-28
Posted by FDA
2014-05-07
Terminated
2014-12-15
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1280-2014. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.